[go: up one dir, main page]

BR0212744A - Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas - Google Patents

Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Info

Publication number
BR0212744A
BR0212744A BR0212744-0A BR0212744A BR0212744A BR 0212744 A BR0212744 A BR 0212744A BR 0212744 A BR0212744 A BR 0212744A BR 0212744 A BR0212744 A BR 0212744A
Authority
BR
Brazil
Prior art keywords
cisplatin
methods
toxicity
reduced toxicity
reduced
Prior art date
Application number
BR0212744-0A
Other languages
English (en)
Inventor
Patrick Fogarty
Original Assignee
Tosk Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosk Inc filed Critical Tosk Inc
Publication of BR0212744A publication Critical patent/BR0212744A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES DE CISPLATINA DE TOXICIDADE REDUZIDA E MéTODOS PARA USO DAS MESMAS". Métodos de uso de agentes ativos de cisplatina, nos quais se observa toxicidade do hospedeiro reduzida, são proporcionados. Nos métodos objeto, uma quantidade eficaz de um agente ativo de cisplatina é administrada ao hospedeiro, em conjunto com a administração de um agente redutor de toxicidade de cisplatina da presente invenção. Também são proporcionadas composições para uso na prática dos métodos objeto, por exemplo, composições farmacêuticas de cisplatina tendo toxicidade reduzida, nas quais o agente, ativo de cisplatina é combinado com um agente redutor de toxicidade de cisplatina, que reduz o nível de toxicidade de cisplatina indesejada, enquanto mantendo uma atividade antiproliferativa de cisplatina. Também são proporcionados métodos dé uso dos métodos e composições objeto, no tratamento de várias condições de doença diferentes.
BR0212744-0A 2001-09-24 2002-09-20 Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas BR0212744A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32456601P 2001-09-24 2001-09-24
PCT/US2002/029669 WO2003026570A2 (en) 2001-09-24 2002-09-20 Reduced toxicity cisplatin formulations and methods for using the same

Publications (1)

Publication Number Publication Date
BR0212744A true BR0212744A (pt) 2005-10-25

Family

ID=23264163

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212744-0A BR0212744A (pt) 2001-09-24 2002-09-20 Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Country Status (18)

Country Link
US (1) US20040258771A1 (pt)
EP (1) EP1435963A4 (pt)
JP (1) JP2005510471A (pt)
KR (1) KR20040048900A (pt)
CN (2) CN101062053A (pt)
AU (1) AU2002334595B2 (pt)
BR (1) BR0212744A (pt)
CA (1) CA2461219A1 (pt)
EA (1) EA007481B1 (pt)
HU (1) HUP0500642A2 (pt)
IL (1) IL160960A0 (pt)
MX (1) MXPA04002707A (pt)
NO (1) NO20041484L (pt)
NZ (1) NZ531936A (pt)
PL (1) PL370867A1 (pt)
SK (1) SK1472004A3 (pt)
WO (1) WO2003026570A2 (pt)
ZA (1) ZA200402229B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815833B2 (en) 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
CN103044338B (zh) * 2012-12-12 2016-08-03 天津医科大学总医院 miR-21小分子抑制剂及应用
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
CR20190274A (es) * 2016-11-11 2019-07-29 Univ Western Health Sciences Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior
CN112574255B (zh) * 2019-09-27 2024-05-10 中国科学院上海有机化学研究所 一类基于有机胂的cdk抑制剂及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5366723A (en) * 1993-03-05 1994-11-22 Istvan Tulok Method of alleviating toxicity originating from treatment with anticancer platinum compounds
JPH06321792A (ja) * 1993-05-18 1994-11-22 Tsumura & Co 副作用軽減剤
US5646011A (en) * 1994-04-08 1997-07-08 Yokoyama; Shiro Cisplatin resistance gene and uses therefor
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6077545A (en) * 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
DE69725747T2 (de) * 1996-08-23 2004-07-29 Sequus Pharmaceuticals, Inc., Menlo Park Liposome enthaltend cisplatin
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
DK0930877T3 (da) * 1996-10-03 2006-08-21 Univ Southern Illinois D-methionin til formindskelse af toksiciteten af platinholdige antitumorforbindelser
TW374078B (en) * 1996-12-25 1999-11-11 Nippon Kayaku Kk Cisplatin micropowder and process for making the same
US6030783A (en) * 1997-01-31 2000-02-29 Massachusetts Institute Of Technology Photo-potentiation of cisplatin chemotherapy
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
WO2000023074A1 (en) * 1998-10-22 2000-04-27 Binex Co., Ltd. Pharmaceutical composition containing decursin
US6130245A (en) * 1998-10-26 2000-10-10 Unitech Pharmaceuticals, Inc. Dinuclear platinum complexes as cisplatin analogs for cancer treatment
PT1307197E (pt) * 2000-05-15 2006-08-31 Celgene Corp Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida

Also Published As

Publication number Publication date
CN1589149A (zh) 2005-03-02
NZ531936A (en) 2006-10-27
CN101062053A (zh) 2007-10-31
EP1435963A4 (en) 2005-10-26
CA2461219A1 (en) 2003-04-03
WO2003026570A3 (en) 2004-01-22
AU2002334595B2 (en) 2007-03-01
WO2003026570A2 (en) 2003-04-03
MXPA04002707A (es) 2005-06-06
PL370867A1 (en) 2005-05-30
SK1472004A3 (en) 2004-10-05
US20040258771A1 (en) 2004-12-23
JP2005510471A (ja) 2005-04-21
HUP0500642A2 (hu) 2005-11-28
EA200400348A1 (ru) 2005-04-28
EP1435963A2 (en) 2004-07-14
KR20040048900A (ko) 2004-06-10
EA007481B1 (ru) 2006-10-27
NO20041484L (no) 2004-04-13
ZA200402229B (en) 2005-03-22
IL160960A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR9611802A (pt) Composições farmacêuticas
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
BR9914419A (pt) Terapia para melhoria da percepção
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
BRPI0413474A (pt) uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
DE69326627D1 (de) Therapeutisches Mittel gegen drohenden Abortus
BRPI0113372B8 (pt) composição veterinária com veículo modificado e ceftiofur
TR200103144T2 (tr) Yeni bileşikler
BR0210063A (pt) Composição estável e uso da mesma
KR920703060A (ko) 제약학적 배합물

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.